# Evaluating Buspirone to Treat Opioid Withdrawal

> **NCT05511909** · PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 100 (estimated)

## Conditions studied

- Opioid Use Disorder
- Opioid Withdrawal
- Opioid Craving
- Anxiety

## Interventions

- **DRUG:** Buspirone
- **DRUG:** Lofexidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05511909
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511909, "Evaluating Buspirone to Treat Opioid Withdrawal". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05511909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*